GSK's ViiV Healthcare Says HIV Treatment Cabenuva's Latest Trial Meets Primary Endpoint
MT newswire2026/10/06 13:4209:42 AM EDT, 10/06/2026 (MT Newswires) -- ViiV Healthcare, which is majority owned by GSK (GSK), said Tuesday that a phase 3b study has met its primary endpoint, showing that at six months, Cabenuva saw "superior rates of viral suppression" compared with oral antiretroviral therapy in adults and adolescents with HIV-1, who had detectable virus when they started the trial. The trial has enrolled 326 participants in eight countries at 85 study sites, the company said. The results follow a previous trial that showed that Cabenuva was superior to daily oral therapy in keeping viral suppression for people with HIV who had reached viral suppression on oral antiretroviral therapy but had a history of adherence challenges, ViiV said. The latest trial addressed a "remaining evidence gap by evaluating direct initiation of the regimen in people who still had detectable virus at study entry," the company said. ViiV said the latest results will now be shared with health regulators. Price: 46.77, Change: +0.24, Percent Change: +0.52
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI data center demand surges, Lumentum (LITE.US) optical component orders booked until 2029
As technology companies race to build high-speed AI data centers, Lumentum's (LITE.US) optical components are nearly "sold out," with orders scheduled through early 2029.
After Amazon and OpenAI, Synopsys (SNPS.US) also "looks to the East": plans to explore cooperation with Chinese AI laboratories on chip design technology
Global chip design software development leader Synopsys (SNPS.US) plans to explore cooperation with Chinese AI laboratories to improve the chip design process.
KBW's Michaud Explains What to Expect from a Pressured Q3 Bank Earnings Season
BUZZ - Morningstar expects Woodside's revenue growth will outpace global peers by the end of this decade
On October 9, Morningstar predicted that the revenue of Australian oil and gas producer Woodside Energy (WDS.AX) will grow by over 30% by 2030, outpacing any of its international peers. Woodside Energy’s share price dropped by 0.6% on the day to 32.12 AUD, after surging 2.6% in the previous trading session. The stock is poised to end a three-week losing streak, with oil prices rising due to escalating tensions in the Middle East, and is set for a 2.8% weekly gain O/R. Morningstar expects Woodside’s revenue to increase as major new projects come online, and forecasts free cash flow to exceed 7 billion USD after 2030, reflecting a 300% rise from 2025. The report added that market sentiment remains bearish, with the current share price below its estimated fair value of 44.00 AUD. Year-to-date, Woodside’s share price has risen 36.2%, while Santos shares are up 41.3%. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several languages. Since automated translations may be inaccurate or lack required context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for the convenience of readers. Reuters accepts no liability for any loss or damage arising from your use of automated translation functions.)
Crypto prices
More
